AMRX - Amneal Pharmaceuticals Inc
(NaN%)
Sell
Weak Growth●Earnings/Profit is Negative
28%
based on last 5 year data.
Income Statement is WEAK
Revenue Growth is 13.42%
Operating Income Growth is 126.42%
Net Income is Negative but improving
Earnings Per Share (EPS) is Negative but improving
Net Margin is -0.46%
Balance Sheet is WEAK
Current Asset to Current Liability Ratio is 1.4
Debt Ratio is 1.02
Current Debt to Net Income Ratio is 2.61
Total Debt to Total Assets Ratio is 0.68
Cash Flow is MODERATE
Cash from Operations Growth is 52.35%
Capital Expenditure not available
Net Increase in Cash is Positive
Long Term Score Trend is NEUTRAL
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Amneal Pharmaceuticals Inc (AMRX) - https://www.amneal.com/
an american pharmaceutical company, amneal develops and produces affordable medicines. the company was built upon a family tradition of quality and integrity. everything amneal does, across the full spectrum of its business, is in service to these guiding principles. amneal is committed to constantly elevating and refining the value it delivers to its customers and patients around the globe.Exchange - NASDAQ
Industry - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Chirag K. Patel
Employees - 3,712
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.
Know the Stock © 2025 and future.